Caspofungin Teva Generics Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

caspofungin teva generics

teva b.v. - kaspofunginas - milteliai infuzinio tirpalo koncentratui - 50 mg; 70 mg - caspofungin

Caspofungin Xellia Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

caspofungin xellia

xellia pharmaceuticals aps - kaspofunginas - milteliai infuzinio tirpalo koncentratui - 70 mg; 50 mg - caspofungin

Onpattro Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

onpattro

alnylam netherlands b.v. - patisiran natrio - amiloidozė, Šeimyniniai - kiti nervų sistemos vaistai - onpattro fluorouracilu gydyti paveldimų transthyretin tarpininkaujant amiloidozė (hattr amiloidozė) suaugusiems pacientams, sergantiems 1 ir 2 etapų polyneuropathy.

Lenalidomide Accord Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

lenalidomide accord

accord healthcare s.l.u. - lenalidomidas - daugybinė mieloma - imunosupresantai - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide sutarimu kartu su dexamethasone nurodomas gydymo mieloma suaugusiųjų pacientų, kurie gavo bent vieną prieš terapija. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Skyrizi Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresantai - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Caspofungin Sandoz Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

caspofungin sandoz

sandoz d.d. - kaspofunginas - milteliai infuzinio tirpalo koncentratui - 50 mg - caspofungin

Caspofungin Sandoz Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

caspofungin sandoz

sandoz d.d. - kaspofunginas - milteliai infuzinio tirpalo koncentratui - 70 mg - caspofungin

octagam Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

octagam

octapharma (ip) sprl - Žmogaus normalusis imunoglobulinas, intraveninis - infuzinis tirpalas - 50 mg/ml - immunoglobulins, normal human, for intravascular adm.

Blenrep Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - daugybinė mieloma - antinavikiniai vaistai - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Nyxthracis (previously Obiltoxaximab SFL) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imuninės serumai ir imunoglobulinai, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.